Head of National Cancer Institute Named Acting FDA Commissioner
Current commissioner, Scott Gottlieb, will be stepping down in April
Policy
FDA Down to 5 Weeks of Funding to Review New Drug Applications
Due to the federal government shutdown, the US Food and Drug Administration has only about 5 weeks of funding left to review new drug applications.
Protecting Your Practice From Data Breaches: An Expert Interview
To shed light on issues of cybersecurity in medical practices, MPR spoke to Michael J Sacopulos, JD, CEO of Medical Risk Institute (MRI), a firm that provides “proactive counsel” to the healthcare community to identify where liability risks originate and to reduce or remove those risks.
FDA: Food Inspections to Resume Despite Ongoing Funding Lapse
The news comes after FDA Commissioner Scott Gottlieb, MD announced last week a plan to recall some furloughed workers to conduct inspections.
American College of Physicians Releases 7th Edition of Ethics Manual
Manual focuses on patient-physician relationship in different scenarios, including telemedicine
How the Government Shutdown Affects FDA Activities
The consequence of the shutdown means the budget appropriated by Congress for the Agency is on hold, resulting in ~7000 of it’s 17,000 employees being furloughed.
Health Officers Express Concerns About Vaccine Exemptions
With new California law eliminating nonmedical exemptions, rise in medical exemptions reported
DEA Proposal Will Significantly Cut Opioid Manufacturing in 2019
Last year, the DEA proposed a 20% reduction in the manufacturing of controlled substances for 2018 compared to 2017.
National Guideline Clearinghouse Offline Due to Funding Cuts
“We believe it is important for providers to have access to evidence-based guidelines when they need them, which is why health insurance providers were an early supporter and sponsor of this project,” Cathryn Donaldson, Director of Communications & Public Affairs for AHIP, said in a statement.
FDA Outlines Plan for Increasing Nonprescription Drug Availability
The draft guidance, Innovative Approaches for Nonprescription Drug Products, applies to drugs under the New Drug Application (NDA) process and “is intended to extend that NDA pathway to include therapeutic indications that have not, historically, been available for use without a prescription,” said Gottlieb in a press statement.
